Ingo GH Schmidt-Wolf

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld et al. · Haematologica · 2007 · 142 citations · Full text

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

Benjamin Kasenda, Gabriele Ihorst, Roland Schroers et al. · Leukemia · 2017 · 90 citations

Hematological Malignancy, Neuro-oncology, Prospective Multicentre Trial +10

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

Hartmut Goldschmidt, Pieter Sonneveld, F. W. Cremer et al. · Annals of Hematology · 2003 · 44 citations

Hematological Malignancy, Oncology, Maintenance Treatment +9

Ondansetron for efficient emesis control during total body irradiation.

N. Schwella, Rainer Schwerdtfeger, Ingo GH Schmidt-Wolf et al. · PubMed · 1994 · 22 citations

CIK Cells and HDAC Inhibitors in Multiple Myeloma

David Stephan, Hans Weiher, Ingo GH Schmidt-Wolf · International Journal of Molecular Sciences · 2017 · 16 citations · Full text

Hematological Malignancy, Cik Cells, Histone Deacetylase +13